Loading...
01/11 10:51
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook: strong financial metrics with increased revenue and improved EBITDA, but offset by macroeconomic pressures and tariff impacts. The Q&A reveals management's optimism about product launches and market leadership, yet concerns about luxury treatment demand and tariff costs persist. Despite improved gross margins and cash position, uncertainties in China and the global market, along with unclear guidance on tariffs, temper the positive financial results. These mixed factors suggest a neutral stock price movement over the next two weeks.
Revenue $69,600,000, an increase from the prior year, driven by strong consumable sales and operational cost discipline.
Adjusted EBITDA $7,300,000, reflecting lower operational spend and higher gross margin compared to the previous year.
Gross Margin 71.9%, up from 63.4% in the prior year, driven by a favorable mix towards consumable sales and improved operational processes.
Consumable Sales $49,400,000, an 8.2% increase year-over-year, with growth across all regions.
Total Active Devices 35,014 units, an increase from 32,530 units at the end of Q1 2024, indicating strong demand for hydro facial devices.
Operating Expenses $60,600,000, a decrease of 7.3% year-over-year, reflecting disciplined expense management.
Cash Position Approximately $373,000,000, an increase from $370,000,000 at the end of Q4 2024, reflecting initial benefits from cost reductions.
Inventory $65,600,000, a decrease from $69,100,000 in December, indicating improved inventory management.
Operating Loss $12,000,000, an improvement from a loss of $17,000,000 in the prior year.
New Product Launches: The HydraLock booster launched in the second half of 2024 marks the most successful branded booster launch in the company's history. A new hydrophilic booster with proprietary PEP9 complex is set to launch in June 2025, targeting signs of aging.
Backbar Initiative: The Backbar initiative, which includes skincare products for in-room HydroFacial services, is set to roll out in the second half of 2025.
Dedicated Skincare Line: A dedicated skincare line is in development, expected to launch in early 2026.
Market Expansion in China: Transitioning to a third-party distribution model in China to simplify operations and lower capital intensity, with initial shipments expected in Q2 2025.
Sales Growth in APAC: Consumable net sales increased by 40.2% in the APAC region, driven by improved sales execution and less discounting.
Operational Efficiencies: Consolidation of production in the U.S. enhances quality, agility, and reduces tariff exposure.
Inventory Management: Improved inventory management led to reduced excess and obsolete inventory charges.
Strategic Focus: The company is focused on enhancing commercial execution, accelerating science-backed innovation, and deepening provider partnerships.
Sales Strategy: A good, better, best device strategy is being implemented to expand provider access and capture market share.
Macroeconomic Pressures: Continued macroeconomic pressures are impacting capital equipment purchasing decisions, leading to a 43.5% year-over-year decline in global device sales.
Tariff Exposure: The company expects approximately $5,000,000 in additional costs due to tariffs in 2025, which could affect profitability.
Regulatory Issues: The transition to a third-party distribution model in China is underway, which may simplify operations but also introduces uncertainty in market access.
Competitive Pressures: The company faces competition in the microdermabrasion market, although it maintains a 60% market share in the U.S. and is the most requested facial treatment.
Economic Factors: The guidance for 2025 assumes continued pressure on delivery systems due to financing challenges and uncertainty in the global market, particularly in China.
Consumer Demand Dynamics: There is a noted softness in luxury treatment adoption, particularly in day spas and plastic surgery channels, which may affect overall sales.
Strategic Focus: Enhancing commercial execution, accelerating science-backed innovation, and deepening provider partnerships.
Commercial Execution: Refined sales structure and enhanced pricing flexibility to drive smarter execution.
Innovation: Launching new products including the hydrophilic booster and Backbar initiative to complement treatments.
Provider Partnerships: Relaunching U.S. Loyalty program in Q3 2025 to reward provider commitment and boost engagement.
Q1 Revenue: $69,600,000, exceeding guidance.
Adjusted EBITDA: $7,300,000, above implied guidance.
Full Year 2025 Revenue Guidance: $270,000,000 to $300,000,000.
Full Year 2025 Adjusted EBITDA Guidance: $15,000,000 to $25,000,000.
Q2 Revenue Guidance: $71,000,000 to $76,000,000.
Capital Expenditures Guidance: $10,000,000 to $15,000,000 for full year 2025.
Tariff Impact: Estimated additional costs of $5,000,000 in 2025.
Adjusted EBITDA: $7,300,000 for Q1 2025, above initial expectations.
Cash Position: Approximately $373,000,000 in cash as of March 31, 2025.
Full Year 2025 Guidance: Projected sales between $270,000,000 to $300,000,000 and adjusted EBITDA of $15,000,000 to $25,000,000.
Capital Expenditures: Expected to be approximately $10,000,000 to $15,000,000 for the full year 2025.
Tariff Impact: Expected to be approximately $5,000,000 of additional costs in 2025.
Sales Guidance for Q2 2025: Projected sales of $71,000,000 to $76,000,000.
The earnings call reveals positive developments: increased revenue and EBITDA guidance, successful price hikes, and promising product launches. Although device sales face challenges, consumables show growth, and stabilization efforts are underway. The company's focus on innovation and strategic pricing, coupled with a positive market response to price increases, indicates a potential stock price uplift. However, management's lack of specific guidance for 2026 and ongoing macroeconomic pressures temper expectations, suggesting a moderate positive sentiment.
Despite exceeding Q1 revenue and EBITDA guidance, concerns about declining gross margins due to tariffs, increased R&D spending, and macroeconomic pressures, such as higher churn and ASP pressure, neutralize the positive impact. The optimistic guidance and strategic initiatives like new product launches and loyalty programs offer potential upside, but uncertainties in execution and financial health create a balanced outlook.
The earnings call presents a mixed outlook: strong financial metrics with increased revenue and improved EBITDA, but offset by macroeconomic pressures and tariff impacts. The Q&A reveals management's optimism about product launches and market leadership, yet concerns about luxury treatment demand and tariff costs persist. Despite improved gross margins and cash position, uncertainties in China and the global market, along with unclear guidance on tariffs, temper the positive financial results. These mixed factors suggest a neutral stock price movement over the next two weeks.
The earnings call highlights several concerning factors: a projected revenue decline, negative EBITDA guidance, and competitive pressures, particularly in international markets. Despite improvements in consumable sales and gross margin, the challenges in China, economic uncertainties, and lack of clarity on the distributor model raise red flags. The share repurchase program is a positive aspect, but overall, the negative guidance and risks outweigh the positives, suggesting a negative stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
